The Seqens Group, a global manufacturer of health, personal care, and specialty ingredients, recently announced a strategic partnership with Novonesis, a sustainable biological solutions provider.
PCAS, a French specialist in complex molecules for the life sciences and specialty chemicals markets, has received an offer for its Canadian subsidiary from Japanese chemicals company DIC.
French API specialist Seqens is investing what it says is a multi-million-dollar sum in its US research and development laboratory at Devens, Massachusetts. The company said the improvements will increase its R&D capability and productivity in the US and strengthen its global network. Completion of the project is expected in October 2022.
Private equity group SK Capital Partners has completed the acquisition of a majority stake in French firm Seqens, at the same time merging portfolio company Wavelength Pharmaceuticals into Seqens to create a leading pharma CDMO with annual revenues of €1.1 billion. The size of SK Capital’s stake was not disclosed.
Seqens, a French provider of pharmaceutical synthesis and specialty ingredients, is planning to invest an undisclosed sum in a second isopropanol (IPA) production plant at Roussillon.
